Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist

@inproceedings{Wang2010NovelGF,
  title={Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist},
  author={Qinghua Wang and Kui Jun Chen and Rui Liu and Fang Hui Zhao and Sandeep Gupta and Nina Zhang and Gerald Joseph Prud'homme},
  booktitle={PloS one},
  year={2010}
}
GLP-1 has a variety of anti-diabetic effects. However, native GLP-1 is not suitable for therapy of diabetes due to its short half-life (t1/2<2 min). To circumvent this, we developed a long-lasting GLP-1 receptor agonist by the fusion of GLP-1 with human IgG2 Fc (GLP-1/hIgG2). ELISA-based receptor binding assay demonstrated that GLP-1/hIgG2 had high binding affinity to the GLP-1R in INS-1 cells (Kd = 13.90±1.52 nM). Upon binding, GLP-1/hIgG2 was rapidly internalized by INS-1 cells in a dynamin… CONTINUE READING
16 Citations
46 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Janeway’s Immunobiology 7 Edition

  • K Murphy, P Travers, M Walport, eds
  • Garland Science, NY
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…